rolipram

Summary

Summary: A phosphodiesterase 4 inhibitor with antidepressant properties.

Top Publications

  1. Paintlia A, Paintlia M, Singh I, Skoff R, Singh A. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia. 2009;57:182-93 pubmed publisher
    ..the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression ..
  2. Chi Z, Hayasaka S, Zhang X, Hayasaka Y, Cui H. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2004;45:2497-502 pubmed
    To investigate effects of rolipram, an inhibitor of type 4 phosphodiesterase, on lipopolysaccharide (LPS)-induced uveitis in Wistar rats. A total of 100 microg LPS was injected into the rat footpad...
  3. DeMarch Z, Giampà C, Patassini S, Martorana A, Bernardi G, Fusco F. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis. 2007;25:266-73 pubmed
    ..The phosphodiesterase type IV inhibitor rolipram increases CREB phosphorylation. Such drug has a protective effect in global ischaemia and embolism in rats...
  4. Zanotti Fregonara P, Liow J, Fujita M, Dusch E, Zoghbi S, Luong E, et al. Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. PLoS ONE. 2011;6:e17056 pubmed publisher
    ..All seven methods were tested on twelve scans with [(11)C](R)-rolipram, which has a low radiometabolite fraction, and on nineteen scans with [(11)C]PBR28 (high radiometabolite fraction)..
  5. Holthoff J, Wang Z, Patil N, Gokden N, Mayeux P. Rolipram improves renal perfusion and function during sepsis in the mouse. J Pharmacol Exp Ther. 2013;347:357-64 pubmed publisher
    ..b>Rolipram, a selective phosphodiesterase 4 (PDE4) inhibitor, has been shown to reduce microvascular permeability and in the ..
  6. Paintlia A, Paintlia M, Singh I, Singh A. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol. 2008;214:168-80 pubmed publisher
    ..Another drug, rolipram (phosphodiesterase-4 inhibitor) ameliorates the clinical severity of EAE via induction of various anti-..
  7. Zhang H, Zhao Y, Huang Y, Dorairaj N, Chandler L, O Donnell J. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology. 2004;29:1432-9 pubmed
    ..It was found that rolipram, a PDE4-selective inhibitor, reversed the amnesic effect in the radial-arm maze test of the MEK inhibitor U0126 ..
  8. Wen R, Zhang M, Qin W, Liu Q, Wang W, Lawrence A, et al. The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats. Alcohol Clin Exp Res. 2012;36:2157-67 pubmed publisher
    ..and 10% (w/v) sucrose operant oral self-administration following treatment with the selective PDE4 inhibitor rolipram (0.0125, 0.025, or 0.05 mg/kg, subcutaneous [s.c.]); rolipram at higher doses (0.05, 0.1, and 0.2 mg/kg, s.c...
  9. Yin Y, Sun W, Li Z, Zhang B, Cui H, Deng L, et al. Effects of combining methylprednisolone with rolipram on functional recovery in adult rats following spinal cord injury. Neurochem Int. 2013;62:903-12 pubmed publisher
    ..The phosphodiesterase 4 (PDE4) inhibitor rolipram has been implicated in promotion of regeneration due to elevating cAMP...

More Information

Publications62

  1. Sanchez A, Puerta C, Ballester S, González P, Arriaga A, Garcia Merino A. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;168:13-20 pubmed
    b>Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS)...
  2. Li Y, Cheng Y, Huang Y, Conti M, Wilson S, O Donnell J, et al. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci. 2011;31:172-83 pubmed publisher
    ..These effects were mimicked by repeated treatment with rolipram in wild-type mice...
  3. Shih C, Lin L, Lai Y, Lai C, Han C, Chen C, et al. Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects. Eur J Pharmacol. 2010;643:113-20 pubmed publisher
    ..3 to 13.7 microM. Genistein (3-300 microM) concentration-dependently displaced 2nM [(3)H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes...
  4. Ong W, Gribble F, Reimann F, Lynch M, Houslay M, Baillie G, et al. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release. Br J Pharmacol. 2009;157:633-44 pubmed publisher
    ..The effects of rolipram, a selective PDE4 inhibitor both in vivo and in vitro and stably overexpressed catalytically inactive PDE4D5 (..
  5. Rutten K, Lieben C, Smits L, Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl). 2007;192:275-82 pubmed
    The selective type IV phosphodiesterase inhibitor, rolipram, has been shown to improve long-term memory and can reverse the cholinergic deficit caused by scopolamine. However, the underlying mechanisms of action of rolipram remain obscure...
  6. Heystek H, Thierry A, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol. 2003;15:827-35 pubmed
    ..These findings indicate that PDE4 inhibitors can affect T cell responses by acting at the DC level and may increase our understanding of the therapeutic implication of PDE4 inhibitors for T(h)1-mediated disorders. ..
  7. Xu R, Rocque W, Lambert M, Vanderwall D, Luther M, Nolte R. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol. 2004;337:355-65 pubmed
    ..0 A), 8-Br-AMP (2.13 A) and the potent inhibitor rolipram (2.0 A)...
  8. Fujioka T, Fujioka A, Duman R. Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci. 2004;24:319-28 pubmed
    ..b>Rolipram, a selective inhibitor of the cAMP-specific phosphodiesterase type 4, was administered to activate the cAMP ..
  9. Johnson F, Reynolds L, Toward T. Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram. Toxicol Appl Pharmacol. 2005;207:257-65 pubmed
    ..The effect of the corticosteroid, dexamethasone, or the phosphodiesterase-4 (PDE4)-inhibitor, rolipram, on these features was studied...
  10. Mammadov E, Aridogan I, Izol V, Açıkalın A, Abat D, Tuli A, et al. Protective effects of phosphodiesterase-4-specific inhibitor rolipram on acute ischemia-reperfusion injury in rat kidney. Urology. 2012;80:1390.e1-6 pubmed publisher
    To investigate the effect of Rolipram, a phosphodiesterase-4-inhibitor, on renal ischemia-reperfusion injury (IRI) in rats. Thirty rats were divided into 5 different groups of 6 rats. Nothing was done to the control group...
  11. Smith K, Leonard D, McDonald J, Tesfaigzi Y. Inflammation, mucous cell metaplasia, and Bcl-2 expression in response to inhaled lipopolysaccharide aerosol and effect of rolipram. Toxicol Appl Pharmacol. 2011;253:253-60 pubmed publisher
    ..When rats were treated with the phosphodiesterase-4 (PDE4) inhibitor, rolipram (10mg/kg), prior to exposure to aerosolized LPS neutrophil numbers in the BAL were reduced at 8h but not at 24 or ..
  12. Bopp T, Dehzad N, Reuter S, Klein M, Ullrich N, Stassen M, et al. Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol. 2009;182:4017-24 pubmed publisher
    ..Prevention of cAMP degradation by application of the phosphodiesterase 4 inhibitor rolipram led to strongly increased suppressive potency of nTreg cells for Th2 cells in vitro and in vivo...
  13. Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, et al. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009;296:L959-69 pubmed publisher
    ..The PDE4 inhibitors roflumilast and rolipram both inhibited fibroblast-mediated contraction of three-dimensional collagen gels and fibroblast chemotaxis ..
  14. Lin C, Lin P, Chen Y, Lin P, Chen I, Lu K, et al. Effects of rolipram on induction of action potential bursts in central snail neurons. Exp Neurol. 2005;194:384-92 pubmed
    Effects of rolipram, a selective inhibitor of phosphodiesterases (PDE) IV, on induction of action potential bursts were studied pharmacologically on the RP4 central neuron of the giant African snail (Achatina fulica Ferussac)...
  15. Gorur S, Celik S, Hakverdi S, Aslantas O, Erdogan S, Aydin M, et al. Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats. Urology. 2008;72:743-8 pubmed publisher
    To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model...
  16. Pearse D, Pereira F, Marcillo A, Bates M, Berrocal Y, Filbin M, et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 2004;10:610-6 pubmed
    ..Inhibition of cAMP hydrolysis by the phosphodiesterase IV inhibitor rolipram prevents this decrease and when combined with Schwann cell grafts promotes significant supraspinal and ..
  17. Sun X, Liu Y, Liu B, Xiao Z, Zhang L. Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse. Exp Neurol. 2012;237:304-11 pubmed publisher
    b>Rolipram, a 3'-5'-cyclic adenosine monophosphate (cAMP)-dependent phosphodiesterase 4 (PDE4) inhibitor, has long been studied for its immune modulating effects in the treatment of experimental autoimmune encephalomyelitis (EAE)...
  18. Chen J, Chen J, Xie Q, Zhu Y. Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram. Acta Pharmacol Sin. 2004;25:1171-5 pubmed
    ..and investigate the effects of selective phosphodiesterase 4 (PDE4) inhibitors (ciclamilast, piclamilast, and rolipram), selective phosphodiesterase 5 (PDE5) inhibitor zaprinast, and cyclooxygenase (COX) inhibitors (aspirin, ..
  19. Juan Fita M, Vargas M, Kaumann A, Hernández Cascales J. Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:324-9 pubmed
    ..We investigated the effects of the PDE4 inhibitor rolipram (1 microM) on the inotropic and cAMP-responses to glucagon in paced right ventricular strips of the rat heart...
  20. Iannotti C, Clark M, Horn K, Van Rooijen N, Silver J, Steinmetz M. A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI. Exp Neurol. 2011;230:3-15 pubmed publisher
    ..treatment using (1) selective depletion of peripheral macrophages with liposomal-encapsulated clodronate, and (2) rolipram, a type 4 phosphodiesterase (PDE4) inhibitor, to promote neuroprotection and improve locomotor recovery following ..
  21. Lourenco C, Kenk M, Beanlands R, DaSilva J. Increasing synaptic noradrenaline, serotonin and histamine enhances in vivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram in rat brain, lung and heart. Life Sci. 2006;79:356-64 pubmed
    ..PDE4 expression and activity are modulated by agents affecting cAMP levels. The selective PDE4 inhibitor (R)-rolipram labeled with C-11 was tested in vivo in rats to analyze changes in PDE4 levels following drug treatments that ..
  22. Layseca Espinosa E, Baranda L, Alvarado Sánchez B, Portales Pérez D, Portillo Salazar H, Gonzalez Amaro R. Rolipram inhibits polarization and migration of human T lymphocytes. J Invest Dermatol. 2003;121:81-7 pubmed
    ..skin diseases; however, an overall study on the effects of specific phosphodiesterase inhibitors, such as rolipram on the processes involved in the extravasation of lymphoid cells has not been performed...
  23. Beaumont E, Whitaker C, Burke D, Hetman M, Onifer S. Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury. Neuroscience. 2009;163:985-90 pubmed publisher
    ..4 (PDE4) subtypes and that their death was attenuated up to 3 days after contusive cervical SCI when rolipram, a specific inhibitor of PDE4, was administered...
  24. Koopmans G, Deumens R, Buss A, Geoghegan L, Myint A, Honig W, et al. Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp Neurol. 2009;216:490-8 pubmed
    ..In the present investigation, the ability of rolipram and thalidomide (FDA approved drugs) to reduce secondary tissue degeneration and improve motor function was ..
  25. Yu M, Chen J, Lai C, Han C, Ko W. Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. Eur J Pharmacol. 2010;627:269-75 pubmed publisher
    ..possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [(3)H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia...
  26. Yang L, Calingasan N, Lorenzo B, Beal M. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol. 2008;211:311-4 pubmed publisher
    b>Rolipram, a specific inhibitor of the phosphodiesterase IV (PDE IV), has recently been shown to exert neuroprotective effects in an Alzheimer transgenic mouse model and in hypoxic-ischemic damage in the rat brain...
  27. Davis J, Gould T. Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav Neurosci. 2005;119:595-602 pubmed
    ..The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition...
  28. Chan A, Huang H, Chien H, Chen C, Lin C, Ko W. Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues. Invest New Drugs. 2008;26:417-24 pubmed publisher
    b>Rolipram has high (PDE4(H)) and low (PDE4(L)) affinities for phosphodiesterase (PDE)-4, respectively...
  29. Rutten K, Basile J, Prickaerts J, Blokland A, Vivian J. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl). 2008;196:643-8 pubmed
    ..The present study investigates the effect of the PDE4 inhibitor rolipram and the PDE5 inhibitor sildenafil on object retrieval performance...
  30. Yao W, Tian X, Chen J, Setterberg R, Lundy M, Chmielzwski P, et al. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact. 2007;7:119-30 pubmed
    ..b>Rolipram is a selective PDE4 inhibitor reported to have anti-inflammatory effects and used in the treatment of asthma and ..
  31. Rutten K, Prickaerts J, Hendrix M, van der Staay F, Sik A, Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol. 2007;558:107-12 pubmed
    ..memory enhancing properties of three selective phosphodiesterase inhibitors (PDE-I) vardenafil (PDE5-I), rolipram (PDE4-I) and BAY 60-7550 (PDE2-I) in the object recognition task...
  32. Schaal S, Garg M, Ghosh M, Lovera L, Lopez M, Patel M, et al. The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury. PLoS ONE. 2012;7:e43634 pubmed publisher
    ..of cyclic adenosine monophosphate (cyclic AMP), via administration of the phosphodiesterase 4 (PDE4) inhibitor Rolipram. The current study sought to determine the optimal neuroprotective dose, route and therapeutic window for ..
  33. Navakkode S, Sajikumar S, Frey J. Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging. J Neurosci. 2005;25:10664-70 pubmed
    b>Rolipram, a selective inhibitor of cAMP-specific phosphodiesterase 4 (PDE4), has been shown to reinforce an early form of long-term potentiation (LTP) to a long-lasting LTP (late LTP)...
  34. Kraft P, Schwarz T, Göb E, Heydenreich N, Brede M, Meuth S, et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis. Exp Neurol. 2013;247:80-90 pubmed publisher
    ..b>Rolipram specifically inhibits the enzyme phosphodiesterase (PDE) 4 thereby preventing the inactivation of the ..
  35. Hosseini Sharifabad A, Ghahremani M, Sabzevari O, Naghdi N, Abdollahi M, Beyer C, et al. Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement. Pharmacol Biochem Behav. 2012;101:311-9 pubmed publisher
    ..In the present study firstly, rats were evaluated for the effects of different doses of the PDE4 inhibitor rolipram and the PDE5 inhibitor sildenafil on spatial memory consolidation in the water maze task...
  36. Werenicz A, Christoff R, Blank M, Jobim P, Pedroso T, Reolon G, et al. Administration of the phosphodiesterase type 4 inhibitor rolipram into the amygdala at a specific time interval after learning increases recognition memory persistence. Learn Mem. 2012;19:495-8 pubmed publisher
    Here we show that administration of the phosphodiesterase type 4 (PDE4) inhibitor rolipram into the basolateral complex of the amygdala (BLA) at a specific time interval after training enhances memory consolidation and induces memory ..
  37. Costa L, Pereira J, Filipe V, Magalhães L, Couto P, Gonzalo Orden J, et al. Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats. Behav Brain Res. 2013;243:66-73 pubmed publisher
    ..Elevation of cAMP via the phosphodiesterase 4 (PDE4) inhibitor, rolipram, decreases neuronal sensitivity to myelin inhibitors, increases growth potential and is neuroprotective...
  38. Bolger G, Peden A, Steele M, MacKenzie C, McEwan D, Wallace D, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278:33351-63 pubmed
    ..PDE4A5 to inhibition by the prototypical PDE4 inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone (rolipram) and attenuated the ability of cAMP-dependent protein kinase to phosphorylate PDE4A5 in intact cells...
  39. Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, et al. Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol. 2007;573:93-9 pubmed
    We employed an ex vivo [(3)H]rolipram binding experiment to elucidate the mechanism of emetic activity of phosphodiesterase 4 inhibitors...
  40. Ramos B, Birnbaum S, Lindenmayer I, Newton S, Duman R, Arnsten A. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron. 2003;40:835-45 pubmed
    ..These data demonstrate that PKA inhibition, rather than activation, is the appropriate strategy for restoring prefrontal cortical cognitive abilities in the elderly. ..
  41. Bretzner F, Plemel J, Liu J, Richter M, Roskams A, Tetzlaff W. Combination of olfactory ensheathing cells with local versus systemic cAMP treatment after a cervical rubrospinal tract injury. J Neurosci Res. 2010;88:2833-46 pubmed publisher
    ..In addition, we assessed a systemic increase of cAMP using the phosphodiesterase inhibitor rolipram. OECs prevented cavity formation, attenuated astrocytic hypertrophy and the retraction of the axotomized ..
  42. Guabiraba R, Campanha Rodrigues A, Souza A, Santiago H, Lugnier C, Alvarez Leite J, et al. The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species. Eur J Pharmacol. 2010;633:85-92 pubmed publisher
    ..Murine macrophages were pretreated with dioclein, rolipram, a PDE4 (cyclic nucleotide phosphosdiesterase type 4) inhibitor, or butylated hydroxytoluene (BHT), an ..
  43. Fujita M, Hines C, Zoghbi S, Mallinger A, Dickstein L, Liow J, et al. Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry. 2012;72:548-54 pubmed publisher
    ..This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measure of this enzyme's activity in the brain of individuals with major ..
  44. Zanotti Fregonara P, Hines C, Zoghbi S, Liow J, Zhang Y, Pike V, et al. Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. Neuroimage. 2012;63:1532-41 pubmed publisher
    ..the use of a population-based input function (PBIF) and an image-derived input function (IDIF) for [(11)C](R)-rolipram kinetic analysis, with the goal of reducing - and possibly eliminating - the number of arterial blood samples ..
  45. Kanes S, Tokarczyk J, Siegel S, Bilker W, Abel T, Kelly M. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience. 2007;144:239-46 pubmed
    ..To test this hypothesis, we studied the effect of an acute treatment of rolipram, an inhibitor of type 4 phosphodiesterases that degrade cAMP, on acoustic startle and prepulse inhibition (PPI) ..
  46. Wang X, Baughman K, Basso D, Strittmatter S. Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann Neurol. 2006;60:540-9 pubmed
    ..Some animals received combination therapy with NgR(310)ecto-Fc plus rolipram, a cyclic adenosine monophosphate phosphodiesterase inhibitor...
  47. Huai Q, Wang H, Sun Y, Kim H, Liu Y, Ke H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure. 2003;11:865-73 pubmed
    ..The crystal structures of the PDE4D2 catalytic domain in complex with (R)- or (R,S)-rolipram suggest that inhibitor selectivity is determined by the chemical nature of amino acids and subtle conformational ..
  48. Zanotti Fregonara P, Zoghbi S, Liow J, Luong E, Boellaard R, Gladding R, et al. Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function. Neuroimage. 2011;54:1903-9 pubmed publisher
    11)C](R)-rolipram provides a measure of the density of phosphodiesterase 4 (PDE4) in brain, an enzyme that metabolizes cAMP...
  49. Sarmiento N, Sánchez Bernal C, Perez N, Sardina J, Mangas A, Calvo J, et al. Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats. Pancreas. 2010;39:639-45 pubmed publisher
    ..Phosphodiesterase and the mitogen-activated protein kinases were inhibited with rolipram and SP600125, respectively, before the induction of AP...
  50. Sprague D, Fujita M, Ryu Y, Liow J, Pike V, Innis R. Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses. Nucl Med Biol. 2008;35:493-500 pubmed publisher
    11)C](R)-Rolipram is a selective radioligand for positron emission tomography (PET) imaging of phosphodiesterase 4, an enzyme that metabolizes 3',5'-cyclic adenosine monophosphate...
  51. Dlaboga D, Hajjhussein H, O Donnell J. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res. 2006;1096:104-12 pubmed
    ..the effects of repeated treatment with the antidepressants desipramine and fluoxetine or the PDE4 inhibitor rolipram on the expression of PDE4D was compared to that of PDE4A and PDE4B, the other two subtypes expressed in the brain...
  52. Tang H, Song Y, Chen J, Chen J, Wang P. Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Respir Crit Care Med. 2005;171:823-8 pubmed
    ..The increases in pulmonary resistance and IL-4 production were both suppressed by the PDE4-selective inhibitor rolipram or the corticosteroid drug dexamethasone...
  53. Nikulina E, Tidwell J, Dai H, Bregman B, Filbin M. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A. 2004;101:8786-90 pubmed
    ..We now show that the phosphodiesterase 4 (PDE4) inhibitor rolipram (which readily crosses the blood-brain barrier) overcomes inhibitors of regeneration in myelin in culture and ..